Literature DB >> 26941446

Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria and AGO Switzerland Regarding the Use of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer.

P Harter1, A du Bois2, S Mahner1, J Pfisterer2, O Ortmann1, C Marth3, D Fink4, F Hilpert2, U Wagner1, J Sehouli5.   

Abstract

The AGO Kommission Ovar already published a statement in 2013, warning about the uncritical use of hyperthermic intraperitoneal chemotherapy (HIPEC) outside controlled studies. This statement has now been updated after the most recent literature was reviewed by AGO Kommission Ovar, the AGO Study Group, NOGGO, AGO Austria and AGO Switzerland. The authors conclude that HIPEC remains experimental. Its use is not recommended and should be rejected outside of prospective controlled trials.

Entities:  

Keywords:  HIPEC; ovarian cancer; statement

Year:  2016        PMID： 26941446      PMCID： PMC4771502          DOI： 10.1055/s-0035-1568169

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN： 0016-5751            Impact factor:   2.915


  15 in total

1.  S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.

Authors:  U Wagner; P Harter; F Hilpert; S Mahner; A Reuß; A du Bois; E Petru; W Meier; P Ortner; K König; K Lindel; D Grab; P Piso; O Ortmann; I Runnebaum; J Pfisterer; D Lüftner; N Frickhofen; F Grünwald; B O Maier; J Diebold; S Hauptmann; F Kommoss; G Emons; B Radeleff; M Gebhardt; N Arnold; G Calaminus; I Weisse; J Weis; J Sehouli; D Fink; A Burges; A Hasenburg; C Eggert
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

2.  Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.

Authors:  Dennis S Chi; Kristina McCaughty; John P Diaz; Jae Huh; Sarah Schwabenbauer; Amanda J Hummer; Ennapadam S Venkatraman; Carol Aghajanian; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

3.  A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.

Authors:  Luis M Chiva; Antonio Gonzalez-Martin
Journal:  Gynecol Oncol       Date:  2014-11-28       Impact factor: 5.482

4.  Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.

Authors:  Philipp Harter; Andreas du Bois; Maik Hahmann; Annette Hasenburg; Alexander Burges; Sibylle Loibl; Martina Gropp; Jens Huober; Daniel Fink; Willibald Schröder; Karsten Muenstedt; Barbara Schmalfeldt; Guenter Emons; Jacobus Pfisterer; Kerstin Wollschlaeger; Hans-Gerd Meerpohl; Georg-Peter Breitbach; Berno Tanner; Jalid Sehouli
Journal:  Ann Surg Oncol       Date:  2006-12       Impact factor: 5.344

5.  Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.

Authors:  Eric Pujade-Lauraine; Uwe Wagner; Elisabeth Aavall-Lundqvist; Val Gebski; Mark Heywood; Paul A Vasey; Birgit Volgger; Ignace Vergote; Sandro Pignata; Annamaria Ferrero; Jalid Sehouli; Alain Lortholary; Gunnar Kristensen; Christian Jackisch; Florence Joly; Chris Brown; Nathalie Le Fur; Andreas du Bois
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

6.  Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer.

Authors:  P Harter; S Mahner; F Hilpert; I Runnebaum; O Ortmann; A Mustea; J Sehouli; A du Bois; U Wagner
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

7.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience.

Authors:  Ingmar Königsrainer; Philipp Horvath; Florian Struller; Eva Maria Grischke; Diethelm Wallwiener; Alfred Königsrainer; Stefan Beckert
Journal:  Langenbecks Arch Surg       Date:  2014-05-11       Impact factor: 3.445

8.  Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer.

Authors:  Philipp Harter; Bianca Beutel; Piero F Alesina; Dietmar Lorenz; Andre Boergers; Florian Heitz; Rita Hils; Christian Kurzeder; Alexander Traut; Andreas du Bois
Journal:  Gynecol Oncol       Date:  2014-01-23       Impact factor: 5.482

9.  HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.

Authors:  Oliver Zivanovic; Alina Abramian; Maximilian Kullmann; Christine Fuhrmann; Christoph Coch; Tobias Hoeller; Hauke Ruehs; Mignon Denise Keyver-Paik; Christian Rudlowski; Stefan Weber; Nicholas Kiefer; Martin L Poelcher; Thore Thiesler; Babak Rostamzadeh; Michael Mallmann; Nico Schaefer; Maryse Permantier; Sandra Latten; Joerg Kalff; Juergen Thomale; Ulrich Jaehde; Walther C Kuhn
Journal:  Int J Cancer       Date:  2014-06-17       Impact factor: 7.396

10.  Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: analysis of the CALYPSO trial.

Authors:  Chee Khoon Lee; Sarah Lord; Tami Grunewald; Val Gebski; Anne-Claire Hardy-Bessard; Jalid Sehouli; Kathrine Woie; Mark Heywood; Christian Schauer; Ignace Vergote; Giovanni Scambia; Annamaria Ferrero; Philipp Harter; Eric Pujade-Lauraine; Michael Friedlander
Journal:  Gynecol Oncol       Date:  2014-10-02       Impact factor: 5.482
View more
  4 in total

Review 1.  Narrative review of cytoreductive surgery and intraperitoneal chemotherapy for peritoneal metastases in ovarian cancer.

Authors:  Thomas Boerner; Oliver Zivanovic; Dennis S Chi
Journal:  J Gastrointest Oncol       Date:  2021-04

Review 2.  Development of new medical treatment for epithelial ovarian cancer recurrence.

Authors:  Rosanna Mancari; Giuseppe Cutillo; Valentina Bruno; Cristina Vincenzoni; Emanuela Mancini; Ermelinda Baiocco; Simone Bruni; Giuseppe Vocaturo; Benito Chiofalo; Enrico Vizza
Journal:  Gland Surg       Date:  2020-08

Review 3.  Hyperthermic intraperitoneal chemotherapy in ovarian cancer: Qui Bono?

Authors:  John Spiliotis
Journal:  Ann Transl Med       Date:  2020-12

4.  Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study.

Authors:  Alaa A Elzarkaa; Waleed Shaalan; Doaa Elemam; Hassan Mansour; Mahmoud Melis; Eduard Malik; Amr A Soliman
Journal:  J Gynecol Oncol       Date:  2018-03-08       Impact factor: 4.401
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.